Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.3. Reserve group antibiotics



Summary of evidence and Expert Committee recommendations

As part of the review of the AWaRe classification and EML listing of antibiotics, the Expert Committee recommended selected Resere group antibiotics be listed as individual medicines on the WHO Model Lists when they have a favourable benefit-risk profile and proven activity against "Critical Priority" or "High Priority" pathogens as identified by the WHO Priority pathogens list. Refer to the 2019 recommendations for new indications for colistin on the EML and EMLc.

Expert Committee report



